轩竹生物，拟赴香港上市，获中国证监会备案通知书

Core Viewpoint - XuanZhu Biotechnology Co., Ltd. is planning to issue up to 77.43 million overseas listed ordinary shares and convert 93.37 million domestic unlisted shares into overseas listed shares, as per the notice from the China Securities Regulatory Commission [1][2]. Group 1: Company Overview - XuanZhu Biotechnology is a China-based biopharmaceutical company with a global vision, headquartered in Beijing and registered in Shijiazhuang, Hebei [3]. - The company has established a comprehensive internal R&D platform to support the development of a competitive and balanced pipeline, with over ten drug assets actively under development [3]. - The therapeutic areas covered by XuanZhu's pipeline include digestive system diseases, oncology, and non-alcoholic steatohepatitis (NASH) [3]. Group 2: Financial and Market Activity - The company has submitted its prospectus to the Hong Kong Stock Exchange twice, on November 25, 2024, and June 13, 2025, with CICC and CMB International acting as joint sponsors [3]. - As of the latest feasible date, XuanZhu has two NDA-approved assets, two drug projects in the NDA registration stage, four projects in Phase I clinical trials, and five projects that have received IND approval [3]. Group 3: Shareholder Information - A total of 17 shareholders are involved in the conversion of domestic unlisted shares to overseas listed shares, with the largest shareholder, Tianjin Zhenxuan Pharmaceutical Technology Partnership, holding 36,049,144 shares [2]. - The total number of shares being converted amounts to 93,368,496 shares [2].